Related Articles
Relationship between adverse events associated with lenvatinib treatment for thyroid cancer and patient prognosis
RECIST 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine‑refractory differentiated thyroid carcinoma
Treatment outcomes of differentiated thyroid cancer with distant metastasis improve by tyrosine kinase inhibitors
IGF2 is a potential factor in RAI‑refractory differentiated thyroid cancer
Proteomic analysis of radioiodine‑refractory differentiated thyroid cancer identifies CHI3L1 upregulation in association with dysfunction of the sodium‑iodine symporter